University of Oxford: Tuberculosis trials

The registry lists 33 Tuberculosis studies with University of Oxford as lead sponsor. 3 are open to participants now and 2 have results posted.

Phase 1 24Phase 2 2No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• ID93/GLA-SE Vaccination + BCG ChallengeRecruitingNCT06670755Not applicable
• Lung Innate Immunity and Microbiome After Tuberculosis ExposureRecruitingNCT06526689
• Immunogenicity of COVID-19 Vaccines in Tuberculosis PatientsRecruitingNCT05571735
• Aerosol BCG Challenge Study in Historically BCG-vaccinated VolunteersCompletedNCT04777721Phase 1Results posted
• MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) InfectionTerminatedNCT02532036Phase 1Results posted
• BCG Revaccination Study in Diabetic and Non-Diabetic AdultsActive, not recruitingNCT06246851Not applicable
• Investigating Immune Responses to Aerosol BCG Challenge in Healthy UK AdultsActive, not recruitingNCT03912207Phase 1
• Aerosol BCG Challenge Trial in Healthy UK AdultsCompletedNCT02709278Phase 1
• PK Study of Anti-TB DrugsCompletedNCT02457208Phase 1
• Heterologous Effects of BCG in Healthy UK AdultsCompletedNCT02380508Not applicable
• Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African AdolescentsCompletedNCT02178748Phase 2
• A Clinical Challenge Study of BCG in Healthy VolunteersCompletedNCT02088892Not applicable
• Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector ImmunityCompletedNCT01954563Phase 1
• Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated AdultsCompletedNCT01879163Phase 1
• Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy AdultsCompletedNCT01829490Phase 1
• Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85ACompletedNCT01683773Phase 1
• Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal RouteCompletedNCT01497769Phase 1
• A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85ACompletedNCT01194180Phase 1
• Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal RouteCompletedNCT01181856Phase 1
• A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIVCompletedNCT00731471Phase 1
• A Study of MVA85A in Healthy Children and InfantsCompletedNCT00679159Phase 2
• A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85ACompletedNCT00653770Phase 1
• A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG VaccinationCompletedNCT00653627Phase 1
• T-Cell Turnover Following Vaccination With MVA85ACompletedNCT00548444Phase 1
• A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCGCompletedNCT00465465Phase 1
• Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape TownCompletedNCT00460590Phase 1
• Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.CompletedNCT00456183Phase 1
• Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous MeningitisStatus unknownNCT00433719Not applicable
• A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCGCompletedNCT00427830Phase 1
• A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month PreviouslyCompletedNCT00427453Phase 1
• A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian VolunteersCompletedNCT00423839Phase 1
• A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.CompletedNCT00423566Phase 1
• The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIVCompletedNCT00395720Phase 1